These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19216247)

  • 1. Drug preemption and the need to reform the FDA consultation process.
    Gilhooley M
    Am J Law Med; 2008; 34(4):539-61. PubMed ID: 19216247
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 3. Who would approve new drugs if there were no FDA?
    Gatty B
    Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 5. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 6. Why doctors should worry about preemption.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
    [No Abstract]   [Full Text] [Related]  

  • 7. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FDA and "privatization"--the drug approval process.
    Rutherford EM
    Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
    [No Abstract]   [Full Text] [Related]  

  • 9. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 10. The FDA, preemption, and the Supreme Court.
    Glantz LH; Annas GJ
    N Engl J Med; 2008 May; 358(18):1883-5. PubMed ID: 18450601
    [No Abstract]   [Full Text] [Related]  

  • 11. Tort reform by regulation: FDA prescription drug labeling rules and preemption of state tort claims.
    Moreland MP
    J Health Life Sci Law; 2007; 1(1):39, 41-62. PubMed ID: 18610730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ejecting the FDA from the courtroom.
    Lancet; 2004 Aug 21-27; 364(9435):638. PubMed ID: 15325808
    [No Abstract]   [Full Text] [Related]  

  • 13. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 14. Buckman extended: federal preemption of state fraud-on-the-FDA statutes.
    Gaddis CA
    Food Drug Law J; 2014; 69(1):113-36, iii. PubMed ID: 24772688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products.
    Struve CT
    Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970
    [No Abstract]   [Full Text] [Related]  

  • 16. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reform bill to speed drugs to residents.
    Hawryluk M
    Provider; 1997 Nov; 23(11):37-8. PubMed ID: 10173669
    [No Abstract]   [Full Text] [Related]  

  • 18. Industry must communicate value and contribution of drugs to Congress and public.
    Gatty B
    Hosp Formul; 1994 May; 29(5):406, 405. PubMed ID: 10133903
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How might cost effectiveness, quality of life, and outcomes data be used by government regulators?
    Gatty B
    Hosp Formul; 1994 Jan; 29(1):70, 69. PubMed ID: 10131268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.